John R. Johnson
Division of Oncology Drug Products (HFD-150)
Center for Drug Evaluation and Research
United States Food and Drug Administration
Rockville
USA
Name/email consistency: high
- Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Johnson, J.R., Cohen, M., Sridhara, R., Chen, Y.F., Williams, G.M., Duan, J., Gobburu, J., Booth, B., Benson, K., Leighton, J., Hsieh, L.S., Chidambaram, N., Zimmerman, P., Pazdur, R. Clin. Cancer Res. (2005)
- End points and United States Food and Drug Administration approval of oncology drugs. Johnson, J.R., Williams, G., Pazdur, R. J. Clin. Oncol. (2003)
- Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Johnson, J.R., Bross, P., Cohen, M., Rothmann, M., Chen, G., Zajicek, A., Gobburu, J., Rahman, A., Staten, A., Pazdur, R. Clin. Cancer Res. (2003)